-
公开(公告)号：WO2013013025A2
公开(公告)日：2013-01-24
申请号：PCT/US2012047370
申请日：2012-07-19
Applicant: MEDIMMUNE LTD , BEDIAN VAHE , WANG YOUZHEN , FOLTZ IAN NEVIN , RATHANASWAMI PALANISWAMI , KANG JASPAL SINGH , KAMAL ADEEIA , STEINER PHILIPP
Inventor： BEDIAN VAHE , WANG YOUZHEN , FOLTZ IAN NEVIN , RATHANASWAMI PALANISWAMI , KANG JASPAL SINGH , KAMAL ADEEIA , STEINER PHILIPP
IPC: A61K39/395
CPC classification number: C07K16/2866 , A61K39/3955 , A61K45/06 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
Abstract translation: 本公开涉及特异性结合CXCR4并抑制CXCR4的生物学活性的抗体或抗原结合片段以及这些试剂的用途。 更具体地，本公开涉及针对CXCR4的完全人抗体或抗原结合片段，其特异性结合CXCR4和这些抗体的用途。 本公开的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所公开的抗体（包括抗原结合片段）可用作诊断和治疗与CXCR4的活性和/或表达相关的疾病。
-
公开(公告)号：WO2009013543A2
公开(公告)日：2009-01-29
申请号：PCT/GB2008050615
申请日：2008-07-23
Applicant: ASTRAZENECA AB , ASTRAZENECA UK LTD , BARRY SIMON THOMAS , BEDIAN VAHE , HEDBERG BRADLEY , KANG JASPAL SINGH , ZHOU QING
Inventor： BARRY SIMON THOMAS , BEDIAN VAHE , HEDBERG BRADLEY , KANG JASPAL SINGH , ZHOU QING
IPC: A61P31/00 , A61K38/17 , A61K39/395 , A61P9/00 , A61P37/00
CPC classification number: C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
Abstract translation: 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地，本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：WO2004071529A3
公开(公告)日：2005-05-06
申请号：PCT/IB2004000366
申请日：2004-02-03
Applicant: PFIZER PROD INC , COHEN BRUCE DAVID , BEDIAN VAHE , WANG HUIFEN FAYE , OBROCEA MIHAIL , GOMEZ-NAVARRO JESUS , CUSMANO JOHN DANIEL , GUYOT DEBORAH JEAN , PAGE KELLY LYNN
Inventor： COHEN BRUCE DAVID , BEDIAN VAHE , WANG HUIFEN FAYE , OBROCEA MIHAIL , GOMEZ-NAVARRO JESUS , CUSMANO JOHN DANIEL , GUYOT DEBORAH JEAN , PAGE KELLY LYNN
CPC classification number: C07K16/2863 , A61K39/39541 , A61K2039/505 , C07K16/2896 , C07K2317/21 , C07K2317/56 , Y02P20/582 , A61K2300/00
Abstract: The present invention relates to a therapeutic method comprising administering antiIGF-IR antibodies, particularly human anti-IGF-IR antibodies to a subject for the treatment of certain disorders preferably in conjunction with administration of another therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment.
Abstract translation: 本发明涉及一种治疗方法，其包括对受试者施用抗-IGF-IR抗体，特别是人抗IGF-1R抗体，用于治疗某些病症，优选与其它治疗剂的施用相结合。 本发明还涉及包含这些抗体的药物组合物和使用抗体及其组合物进行治疗的方法。
-
公开(公告)号：WO03040170A9
公开(公告)日：2004-06-10
申请号：PCT/US0236107
申请日：2002-11-08
Applicant: PFIZER PROD INC , ABGENIX INC , BEDIAN VAHE , GLADUE RONALD P , CORVALAN JOSE , JIA XIAO-CHI , FENG XIAO
Inventor： BEDIAN VAHE , GLADUE RONALD P , CORVALAN JOSE , JIA XIAO-CHI , FENG XIAO
IPC: A01H5/00 , A01K67/027 , A61K31/7088 , A61K35/76 , A61K39/395 , A61K48/00 , A61P13/08 , A61P13/10 , A61P35/00 , A61P35/02 , A61P43/00 , C07K20060101 , C07K16/28 , C07K16/40 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12N15/00 , C12N15/11 , C12N15/63
CPC classification number: C07K16/2866 , A01K2217/05 , A61K39/3955 , A61K45/06 , A61K48/00 , A61K2039/505 , A61N5/062 , A61N5/10 , C07K16/2878 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.
Abstract translation: 本发明涉及与CD40，优选人CD40特异性结合并且作为CD40激动剂起作用的抗体及其抗原结合部分。 本发明还涉及人抗CD40抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗CD40抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗CD40抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗-CD40抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物。
-
公开(公告)号：WO2013013025A3
公开(公告)日：2013-01-24
申请号：PCT/US2012/047370
申请日：2012-07-19
Applicant: MEDIMMUNE LIMITED , BEDIAN, Vahe , WANG, Youzhen , FOLTZ, Ian, Nevin , RATHANASWAMI, Palaniswami , KANG, Jaspal, Singh , KAMAL, Adeeia , STEINER, Philipp
Inventor： BEDIAN, Vahe , WANG, Youzhen , FOLTZ, Ian, Nevin , RATHANASWAMI, Palaniswami , KANG, Jaspal, Singh , KAMAL, Adeeia , STEINER, Philipp
IPC: A61K39/395
Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
-
Patent Agency Ranking
公开(公告)号：WO2010032060A1
公开(公告)日：2010-03-25
申请号：PCT/GB2009/051217
申请日：2009-09-18
Applicant: MEDIMMUNE LLC , MEDIMMUNE LIMITED , BEDIAN, Vahe , FOLTZ, Ian , JENKINS, David
Inventor： BEDIAN, Vahe , FOLTZ, Ian , JENKINS, David
IPC: C07K16/22 , A61K39/395
CPC classification number: C07K16/28 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K2039/505 , C07H21/04 , C07K14/475 , C07K16/22 , C07K2317/565 , C07K2317/92
Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
Abstract translation: 本发明涉及针对DLL4的靶向结合剂及其用途。 更具体地，本发明涉及针对DLL4的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与DLL4的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：WO2009097325A1
公开(公告)日：2009-08-06
申请号：PCT/US2009/032224
申请日：2009-01-28
Applicant: MEDIMMUNE LIMITED , BEDIAN, Vahe , DALL'ACQUA, William , WU, Herren , BOWEN, Michael , BROWN, Jeffrey , STANNARD, Chris
Inventor： BEDIAN, Vahe , DALL'ACQUA, William , WU, Herren , BOWEN, Michael , BROWN, Jeffrey , STANNARD, Chris
IPC: A61K39/00
CPC classification number: C07K16/22 , A61K31/282 , A61K31/337 , A61K31/4375 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/573 , A61K31/7068 , A61K38/1793 , A61K39/3955 , A61K39/39558 , A61K39/39591 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
Abstract translation: 描述了针对血管生成素-2的稳定抗体和这种抗体的用途。 还提供了核酸和氨基酸序列，杂交瘤或用于表达这种抗体的其它细胞系。
-
8.发明申请BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF-909 审中-公开胰岛素样生长因子的特异性蛋白质与其用途-909
公开(公告)号：WO2008152422A2
公开(公告)日：2008-12-18
申请号：PCT/GB2008/050436
申请日：2008-06-11
Applicant: ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BEDIAN, Vahe , CARTLIDGE, Susan, Ann , GAZIT-BORNSTEIN, Gadi , RAEBER, Olivia , TONGE, David, William , YANG, Xiao-Dong
Inventor： BEDIAN, Vahe , CARTLIDGE, Susan, Ann , GAZIT-BORNSTEIN, Gadi , RAEBER, Olivia , TONGE, David, William , YANG, Xiao-Dong
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92
Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described.
Abstract translation: 描述了结合蛋白，例如针对IGF-II的抗体与IGF-1的交叉反应性和这种抗体的用途。
-
公开(公告)号：WO2003040170A3
公开(公告)日：2003-05-15
申请号：PCT/US2002/036107
申请日：2002-11-08
Applicant: PFIZER PRODUCTS INC. , ABGENIX, INC. , BEDIAN, Vahe , GLADUE, Ronald, P. , CORVALAN, Jose , JIA, Xiao-Chi , FENG, Xiao
Inventor： BEDIAN, Vahe , GLADUE, Ronald, P. , CORVALAN, Jose , JIA, Xiao-Chi , FENG, Xiao
IPC: A61K39/395
Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.
-
公开(公告)号：WO2008112004A3
公开(公告)日：2009-04-02
申请号：PCT/US2007075120
申请日：2007-08-02
Applicant: ASTRAZENECA AB , FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
Inventor： FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
CPC classification number: C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
Abstract: Targeted binding agents, such antibodies directed to the antigen aVß6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen aVß6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
Abstract translation: 描述了靶向结合剂，针对抗原aVβ6的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原aVβ6的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.022 seconds)
